Publications

Export 13 results:
Auteur Title [ Type(Desc)] Année
Filtres: Auteur is Blennow, Kaj  [Enlever les filtres]
Journal Article
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JLuis, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R et al..  2014.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.. Lancet Neurol. 13(6):614-29.
Kang MSu, Aliaga AAliaga, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA et al..  2020.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.. Mol Psychiatry.
Picard C, Nilsson N, Labonte A, Auld D, Rosa-Neto P, Ashton NJ, Zetterberg H, Blennow K, Breitner JCS, Villeneuve S et al..  2021.  Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.. Alzheimers Dement.
Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C et al..  2016.  Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.. J Alzheimers Dis. 52(1):51-64.
Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D et al..  2017.  Consensus guidelines for lumbar puncture in patients with neurological diseases.. Alzheimers Dement (Amst). 8:111-126.
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
Pascoal TA, Benedet AL, Ashton NJ, Kang MSu, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK et al..  2021.  Microglial activation and tau propagate jointly across Braak stages.. Nat Med. 27(9):1592-1599.
Tissot C, Benedet AL, Therriault J, Pascoal TA, Lussier FZ, Saha-Chaudhuri P, Chamoun M, Savard M, Mathotaarachchi SS, Bezgin G et al..  2021.  Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease.. Alzheimers Res Ther. 13(1):69.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
Kang MSu, Shin M, Ottoy J, Aliaga AAliaga, Mathotaarachchi S, Quispialaya K, Pascoal TA, D Collins L, Chakravarty MM, Mathieu A et al..  2021.  Preclinical longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic.. J Cereb Blood Flow Metab. :271678X211035625.
Pascoal TA, Benedet AL, Ashton NJ, Kang MSu, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK et al..  2021.  Publisher Correction: Microglial activation and tau propagate jointly across Braak stages.. Nat Med. 27(11):2048-2049.
Paterson RW, Benjamin LA, Mehta PR, Brown RL, Athauda D, Ashton NJ, Leckey CA, Ziff OJ, Heaney J, Heslegrave AJ et al..  2021.  Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes.. Brain Commun. 3(3):fcab099.
Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, Lerch O, Laczo J, Cechova K, Clarin M et al..  2022.  Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.. Clin Chem Lab Med. 60(2):207-219.